logo
Select company
Select metric
14.24%Cash to Assets Ratio
VS
Market
66
Sector
33
Industry
20
History
15
$ 2.24Close
$ 1.95 - $ 5.35 52-Week Range
Ticker Information

Ticker

CRDF

Company Name

CARDIFF ONCOLOGY INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

CARDIFF ONCOLOGY INC - Cash to Assets Ratio Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

CRDF - Cash to Assets Historical data
DateTotal AssetsCash and EquivalentsCash to Assets Ratio
6/30/2025$ 75.74M$ 10.78M14.24%
3/31/2025$ 84.81M$ 24.09M28.41%
12/31/2024$ 97.19M$ 51.47M52.96%
9/30/2024$ 62.9M$ 13.04M20.73%
6/30/2024$ 66.05M$ 25.5M38.61%
3/31/2024$ 74.04M$ 18.66M25.2%
12/31/2023$ 81.64M$ 21.66M26.53%
9/30/2023$ 88.45M$ 15.23M17.22%
6/30/2023$ 97.45M$ 19.37M19.87%
3/31/2023$ 106.55M$ 15.02M14.09%
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • CARDIFF ONCOLOGY INC's latest trailing twelve months (TTM) Cash to Assets stands at 92.28%.
  • Over the past 5 years, CARDIFF ONCOLOGY INC's average Cash to Assets has been 27.15%.
  • The median Cash to Assets for CARDIFF ONCOLOGY INC during this period was 16.6%
  • CARDIFF ONCOLOGY INC reached its highest Cash to Assets over the past 5 years at 97.22%.
  • The lowest Cash to Assets recorded by CARDIFF ONCOLOGY INC in the same timeframe 7.36%

CARDIFF ONCOLOGY INC's Cash to Assets vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

Cash to Assets Benchmarks
CompanyCash to Assets
MREO : MEREO BIOPHARMA GROUP PLC 89.61%AVTX : AVALO THERAPEUTICS INC 33.42%HUMA : HUMACYTE INC 63.58%COYA : COYA THERAPEUTICS INC 88.95%VTGN : VISTAGEN THERAPEUTICS INC 71.07%ABEO : ABEONA THERAPEUTICS INC 66.55%ABVC : ABVC BIOPHARMA INC 6.63%LYEL : LYELL IMMUNOPHARMA INC 26.04%CURX : CURANEX PHARMACEUTICALS INC 13.83%MNPR : MONOPAR THERAPEUTICS 73.33%

Definition of Cash to Assets Ratio

[Calculation] The Cash to Assets Ratio expresses a company’s cash and cash equivalents [CashnEq] as a percentage of total [Assets].
CashnEq / Assets
(=) Cash to Assets
Cash to Assets for CARDIFF ONCOLOGY INC is calculated as follows: CashnEq [ $ 36.41M ] / Assets [ $ 39.45M ]
(=) Cash to Assets [ 92.28% ]

CRDF - Cash to Assets Ratio, Last 5 years

7.36%

Minimum

Jun 30, 2021

97.22%

Maximum

Dec 31, 2020

27.15%

Average

16.6%

Median

Cash to Assets Benchmark Analysis

The chart above depicts the distribution of Cash to Assets for companies in the Total Stock Market. The average Cash to Assets of the companies is 9.83% with a standard deviation of 9.6%.
The following table provides additional summary stats:
Cash to Assets in the Market:
filtered constituents3.94K
min0%
max40.89%
average9.83%
median6.44%
std9.6%